ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On August10, 2017, EnteroMedics Inc. (the “Company”) agreed to issue warrants to purchase an aggregate of 2,581,750 shares of common stock, par value $0.01 per share, of the Company, to certain parties (each, a “Holder”) to the Securities Purchase Agreement (as amended, the “Purchase Agreement”), dated November4, 2015, between the Company and the other parties named therein, as consideration for the waiver by each of the Holders of their right to participate in future securities offerings by the Company, which rights were granted to the Purchase Agreement. The warrants will be in substantially the same form, and on the same terms as, the warrants issued to the underwritten public offering that the Company announced on August10, 2017. The warrants and shares of common stock underlying the warrants will be registered under the Company’s effective registration statement on FormS-3 and offered to a prospectus supplement that will describe the specific terms of the offering of the warrants.

The information furnished herewith to Item 7.01 of this Current Report is being “furnished” in accordance with General Instruction B.2 of Form8-K and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.